PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG International Canada Expands Operations to Directly Sell Interventional Oncology Products - DC Bead®, DC BeadM1® and Bead Block® Now Sold Directly to Specialist Physicians Across Canada - BTG-IM.com
BTG International Canada Expands Operations to Directly Sell Interventional Oncology Products

 

NewswireToday - /newswire/ - Ottawa, Ontario, Canada, 2016/03/10 - DC Bead®, DC BeadM1® and Bead Block® Now Sold Directly to Specialist Physicians Across Canada - BTG-IM.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG International Canada, Inc., a part of the international specialty healthcare company BTG, is now selling its interventional oncology products DC Bead®, DC BeadM1® and Bead Block® direct-to-physicians in Canada. All three products were previously distributed in Canada by LivaNova PLC.

BTG has expanded its commercial presence in Canada in recent months and built an expert commercial team to directly promote and distribute its products. In 2015, BTG began selling its radioembolization product TheraSphere® and will now sell key interventional oncology products DC Bead®, DC BeadM1®, and Bead Block® directly in the Canadian marketplace.

“Being a global leader in interventional medicine, we’re proud to establish a commercial presence in Canada and pleased to begin to supply BTG products directly to healthcare professionals across the country,” said Brad Pearson, director, commercial operations at BTG International Canada Inc.

Canadian customers may call 1-844-292-1BTG (1284) to order DC Bead®, DC BeadM1®, and Bead Block® directly from BTG International Canada. To order TheraSphere® directly in Canada, customers may call BTG International Canada at 1-866-363-3330.

About DC Bead®
The gold-standard drug-eluting bead, DC Bead® is supported by more than 10 years’ experience and 100 peer-reviewed publications reporting outcomes in over 3,500 patients with liver cancer. DC Bead® has been shown in studies to offer improved clinical and patient outcomes, including excellent tolerability versus conventional TACE, and high rates of five-year survival data.1-8

Developed and manufactured by BTG, DC Bead® received Canadian approval in 2006. DC Bead® is an embolic drug-eluting bead capable of loading and releasing chemotherapeutic agents for the treatment of primary liver cancer (hepatocellular carcinoma or HCC) and liver metastases from colorectal cancers.

About DC BeadM1®
Approved in Canada in 2011, DC BeadM1® is a subset of the smallest DC Bead®. The narrow size distribution of DC BeadM1® offers greater uniformity and concentration of bead and drug distribution in the tumor.9

About Bead Block®
Bead Block® embolic beads have a unique structure PVA hydrogel cross-linked with acrylic polymer to ensure smooth delivery and targeted, effective embolization. Bead Block® received Canadian approval in 2005.

All bead products are used in minimally invasive (non-surgical) procedures performed by an interventional radiologist.

About TheraSphere®
Manufactured in Ottawa, Canada, TheraSphere® was granted a Canadian medical device license in 2002. TheraSphere® is a well-tolerated liver cancer therapy that consists of millions of small glass microspheres containing radioactive yttrium-90. The product is injected by a physician into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood flow.

About BTG Interventional Medicine
BTG Interventional Medicine (btg-im.com) is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

For more information:

Canadian Media Inquiries: Eileen Tobey, beSPEAK Communications Inc.
P: +1 416-540-4047 - E: Eileen[.]bespeakcommunications.com.

Investor Relations Inquiries: Andy Burrows, VP Corporate & Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

References:
1. DC Bead Clinical Bibliography. Jan 2016. Available on Request
2. Varela M et al. J Hepatol 46 (2007): 474-81
3. Poon RTP et al. Clin Gastroenterol and Hepatol 5 (2007): 1100-08.
4. Lammer J et al. Cardiovasc Intervent Radiol 33 (2010): 41-52
5. Liu Y-S et al. Korean J Radiol 16 (2015): 125-132.
6. Song MJ et al. Eur J Gastroenterol Hepatol 23 (2011): 521-7.
7. Burrel M et al. J Hepatol 56 (2012): 1330-5.
8. Malagari K et al. Cardiovasc Intervent Radiol 35 (2012): 1119-28.
9. Dreher M et al. J Vasc Interv Radiol 23 (2012): 257-64.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG International Canada Expands Operations to Directly Sell Interventional Oncology Products

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG Interventional Med. |
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)7773 251178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)